2890 - Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial

Co-Author(s)

• 

  John S. Bradley, MD

  Distinguished Professor of Pediatrics
  University of San Diego School of Medicine, Rady Children's Hospital
  San Deigo, California, United States
• ER

  Emmanuel Roilides, MD, PhD

  3rd
  Thessaloniki, Thessaloniki, Greece

Presenting Author(s)

• RE

  Richard England, MD, PhD

  Pfizer Inc., Groton
  Groton, CT, United States

  Slides

Co-Author(s)

• MT

  Margaret Tawadrous, MD, MS

  Pfizer, Inc
  Groton, Connecticut, United States
• JY

  Jean Yan, M.S.

  Pfizer Inc., Sanford, Florida, USA
  Sanford, Florida, United States
• ES

  Elena Soto, PhD

  Pfizer R&D UK Ltd., Canterbury, Kent, UK
  Canterbury, Kent, England, United Kingdom
• GS

  Gregory Stone, PhD

  Director of Microbiology
  Pfizer, Inc.
  Groton, Connecticut, United States
• SK

  Shweta Kamat, MD

  Dr
  Pfizer India
  MUMBAI, Maharashtra, India